Parkinson's disease

44 trials 13 recruiting MedDRA PT
44 Registered trials
13 Recruiting
34 Unique sponsors
29 Unique IMPs
36 Commercial trials
Drug classes (ATC)
— ATC code not specified 31
N Neurology/Psychiatry (ATC N) 8
V Various (ATC V) 1
D Dermatology (ATC D) 2
L Oncology (ATC L) 1
P Parasitology (ATC P) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 26 substances
Monoclonal antibody (neural, humanized) 1 substance
Monoclonal antibody (neural) 1 substance
Kinase inhibitor 1 substance
Phase III: 6 Phase II/III: 2 Phase II: 17 Phase I: 5 Phase I (Other): 9 Phase I (First in Human): 2 Other: 3

Filter these 44 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 44 trials

Phase III

6 trials
  • Cerevel Therapeutics LLC Commercial
    TAVAPADON
    2024-512123-37-00 8 countries 2021 n=487
    Ended
  • F. Hoffmann-La Roche AG Commercial
    PRASINEZUMAB
    2025-522683-32-00 9 countries 2026 n=405
    Recruiting
  • Neuroderm Ltd. Commercial
    CARBIDOPA, LEVODOPA
    2024-511940-20-00 9 countries 2020 n=156
    Ended
  • Zambon Biotech S.A. Commercial
    LEVODOPA, CARBIDOPA MONOHYDRATE
    2025-521772-57-00 3 countries 2025 n=91
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona Academic
    SAFINAMIDE
    2025-521512-20-00 1 country n=60
    Pending
  • Universitaetsklinikum Tuebingen AöR Academic
    ENTACAPONE, LEVODOPA, CARBIDOPA MONOHYDRATE
    2025-521048-39-00 1 country 2025 n=150
    Recruiting

Phase II/III

2 trials
  • F. Hoffmann-La Roche AG Commercial
    PRASINEZUMAB
    2023-507132-21-00 6 countries 2021 n=398
    Ended
  • Institut National De La Sante Et De La Recherche Medicale Academic
    (1-(11C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE; 3-AMINO-4-[2-[[METHYL((111C)METHYL)AMINO]METHYL]PHENYL]SULFANYLBENZONITRILE
    2024-516610-38-00 1 country n=50
    Pending

Phase II

17 trials
  • AC Immune S.A. Commercial
    IOFLUPANE (123I); PD01B
    2022-500292-31-00 2 countries 2023 n=121
    Recruiting
  • Bial R&D Investments S.A. Commercial
    5,7-DIMETHYL-N-((1R,4R)-4-(PENTYLOXY)CYCLOHEXYL)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE
    2022-501783-18-00 8 countries 2023 n=96
    Ended
  • BioArctic AB Commercial
    EXIDAVNEMAB
    2024-511222-30-00 2 countries 2024 n=36 Orphan
    Ended
  • Biogen Idec Research Limited Commercial
    N2-(3-(2-(2H-1,2,3-TRIAZOL-2-YL)PROPAN-2-YL)-1-CYCLOPROPYL-1H-PYRAZOL-5-YL)-N4-ETHYL-5-(TRIFLUOROMETHYL)PYRIMIDINE-2,4-DIAMINE
    2023-505645-12-00 7 countries 2022 n=311
    Ended
  • Cavion Inc. Commercial
    SUVECALTAMIDE
    2024-515177-94-00 3 countries 2023 n=132
    Ended
  • Cerevance Beta Inc. Commercial
    1-[2-[4-(2,4-DIFLUOROPHENOXY)PIPERIDIN-1-YL]-3-[[(3R)-OXOLAN-3-YL]AMINO]-7,8-DIHYDRO-5H-PYRIDO[3,4-B]PYRAZIN-6-YL]ETHANONE
    2024-516811-25-00 5 countries 2025 n=148
    Ended
  • Clinuvel Europe Limited Commercial
    AFAMELANOTIDE
    2022-502207-30-00 1 country n=10
    Not authorised
  • Clinuvel Europe Limited Commercial
    AFAMELANOTIDE
    2022-502207-30-01 1 country n=6
    Ended
  • F. Hoffmann-La Roche AG Commercial
    PRASINEZUMAB
    2023-504472-24-00 4 countries 2024 n=238
    Recruiting
  • Il-Yang Pharm Co. Ltd. Commercial
    RADOTINIB DIHYDROCHLORIDE
    2024-516549-37-00 1 country 2021 n=40
    Ended
  • Luye Pharma Switzerland AG Commercial
    ROTIGOTINE
    2025-521172-64-00 1 country 2026 n=24
    Ended
  • Neuroderm Ltd. Commercial
    CARBIDOPA, LEVODOPA
    2024-513548-27-00 4 countries 2016 n=42
    Ended
  • Neuron23 Inc. Commercial
    NEU-411 MALEATE
    2024-515448-22-00 3 countries n=60
    Pending
  • UCB Biopharma Commercial
    MINZASOLMIN
    2022-500424-30-00 6 countries 2022 n=283
    Ended
  • Karolinska University Hospital Academic
    BENSERAZIDE HYDROCHLORIDE, LEVODOPA; MONTELUKAST SODIUM
    2023-504278-39-00 1 country 2024 n=98
    Recruiting
  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum) Academic
    FASUDIL HYDROCHLORIDE; QUININE DIHYDROCHLORIDE
    2024-517413-33-00 1 country 2026 n=75
    Recruiting
  • Stichting Radboud University Medical Center Academic
    APOMORPHINE HYDROCHLORIDE HEMIHYDRATE; BENSERAZIDE HYDROCHLORIDE, LEVODOPA; DOMPERIDONE; RIFAXIMIN
    2024-510629-24-00 1 country 2025 n=81
    Recruiting

Phase I

5 trials
  • AC Immune S.A. Commercial
    IMP not specified
    2024-515664-31-00 1 country 2025 n=46
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-511110-21-00 1 country 2024 n=140
    Recruiting
  • Institut De Recherches Internationales Servier IRIS Commercial
    IMP not specified
    2024-519381-53-00 1 country 2022 n=103
    Ended
  • Modag GmbH Commercial
    IMP not specified
    2023-506965-72-00 1 country n=28
    Pending
  • Prevail Therapeutics Inc. Commercial
    IMP not specified
    2024-513411-27-00 2 countries n=10
    Pending

Phase I (Other)

9 trials
  • Bial Portela & Ca S.A. Commercial
    IMP not specified
    2025-520840-14-00 1 country 2025 n=32
    Ended
  • Bial R&D Investments S.A. Commercial
    IMP not specified
    2025-520754-11-00 1 country 2025 n=40
    Recruiting
  • CCDRD Cooperative Clinical Drug Research and Development AG Commercial
    LEVODOPA
    2023-504687-42-00 1 country 2023 n=26
    Ended
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2023-504412-14-00 1 country 2022 n=20
    Ended
  • H. Lundbeck A/S Commercial
    IMP not specified
    2023-507785-12-00 3 countries 2024 n=54
    Ended
  • Herantis Pharma Oyj Commercial
    IMP not specified
    2024-512532-30-00 1 country 2024 n=40
    Ended
  • Integrative Research Laboratories Sweden AB Commercial
    IRL757
    2025-523612-37-00 4 countries 2026 n=125
    Recruiting
  • Mission Therapeutics Limited Commercial
    IMP not specified
    2024-517310-15-00 3 countries n=18
    Pending
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-507959-29-00 1 country 2024 n=6
    Ended

Phase I (First in Human)

2 trials
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2024-517566-42-00 1 country n=12
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2025-522261-30-00 1 country 2025 n=2
    Recruiting

Other

3 trials
  • Eva Pharma For Pharmaceuticals And Medical Appliances SAE Commercial
    IMP not specified
    2024-515840-21-00 1 country 2024 n=48
    Ended
  • Eva Pharma For Pharmaceuticals And Medical Appliances SAE Commercial
    IMP not specified
    2024-515841-41-00 1 country 2024 n=48
    Ended
  • Orion Corporation Commercial
    IMP not specified
    2026-525449-57-00 1 country 2026 n=40
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 5 Phase I, Phase II/III, Phase I (Other), Phase II, Phase III 3
AC Immune S.A. Commercial 2 Phase I, Phase II 2
Eva Pharma For Pharmaceuticals And Medical Appliances SAE Commercial 2 Other 0
Bial R&D Investments S.A. Commercial 2 Phase I (Other), Phase II 1
Clinuvel Europe Limited Commercial 2 Phase II 0
Neuroderm Ltd. Commercial 2 Phase II, Phase III 0
Centre Hospitalier Universitaire De Nantes Academic 2 Phase I (First in Human) 1
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I 0
Modag GmbH Commercial 1 Phase I 0
Prevail Therapeutics Inc. Commercial 1 Phase I 0
Orion Corporation Commercial 1 Other 0
Bial Portela & Ca S.A. Commercial 1 Phase I (Other) 0
CCDRD Cooperative Clinical Drug Research and Development AG Commercial 1 Phase I (Other) 0
H. Lundbeck A/S Commercial 1 Phase I (Other) 0
Herantis Pharma Oyj Commercial 1 Phase I (Other) 0
Integrative Research Laboratories Sweden AB Commercial 1 Phase I (Other) 1
Mission Therapeutics Limited Commercial 1 Phase I (Other) 0
Novartis Pharma AG Commercial 1 Phase I (Other) 0
BioArctic AB Commercial 1 Phase II 0
Biogen Idec Research Limited Commercial 1 Phase II 0
New trials by year
2020
1
2021
3
2022
4
2023
4
2024
9
2025
8
2026
5
← All indication landscapes